Whalesbook
Jeevan Scientific Technology Ltd. Reports Robust FY26 Financial Performance
Jeevan Scientific Technology Ltd. has announced strong financial results for the fiscal year ended March 31, 2026, with significant growth in both revenue and profit on a standalone and consolidated basis. The company also revealed key corporate actions related to its employee stock option plan.
Reader Takeaway: Revenue and profit growth boost investor confidence; ESOPs may impact EPS going forward.
What just happened
Jeevan Scientific Technology Ltd. (JSTL) reported its financial results for the year ended March 31, 2026. Standalone revenue increased by 23.7% to ₹53.93 crore from ₹43.61 crore in the previous year. Consolidated revenue saw a larger jump of 31.4% to ₹61.54 crore from ₹46.84 crore.
Profitability also improved markedly. Standalone net profit rose to ₹1.65 crore from ₹0.74 crore. On a consolidated basis, profit jumped to ₹1.03 crore from a marginal ₹0.06 crore in the prior year.
The company's board also approved the grant of 4,80,000 stock options under the JSTL ESOP Scheme 2016. Additionally, 1,61,250 equity shares were allotted upon exercise of options, bringing the total share capital to 2,00,80,215 shares.
Why this matters
The double-digit growth in revenue and substantial profit increase signals a positive operational performance for JSTL. The unmodified audit opinion from statutory auditors provides assurance on the accuracy of these financial statements, which is crucial for investor confidence.
The backstory
JSTL primarily operates in clinical research services. The company has been focusing on expanding its services and client base. The ESOP scheme is a standard mechanism to retain and incentivize key employees.
What changes now
Investors will be looking at how the increased equity base from ESOP allotments impacts future earnings per share (EPS). The continued focus on clinical research services is expected to be the main driver of future growth.
Risks to watch
Potential dilution of earnings per share due to the allotment of new equity shares under the ESOP scheme is a key point to monitor.
Peer comparison
(No peer comparison data available in the filing.)
Context metrics (time-bound)
Standalone Revenue FY26: ₹53.93 crore vs FY25: ₹43.61 crore.
Consolidated Revenue FY26: ₹61.54 crore vs FY25: ₹46.84 crore.
Standalone Profit FY26: ₹1.65 crore vs FY25: ₹0.74 crore.
Consolidated Profit FY26: ₹1.03 crore vs FY25: ₹0.06 crore.
What to track next
Future quarterly results and management commentary on business outlook and expansion plans will be key for investors to track.